Sanford C. Bernstein initiated coverage on shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in a research note published on Thursday morning, Marketbeat reports. The brokerage issued a market perform rating and a $57.00 price objective on the stock.

A number of other research firms have also issued reports on IONS. BMO Capital Markets restated an outperform rating and set a $62.00 price target (up previously from $59.56) on shares of Ionis Pharmaceuticals in a report on Tuesday, July 25th. Needham & Company LLC reiterated a buy rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Stifel Nicolaus reiterated a hold rating and issued a $42.00 price objective on shares of Ionis Pharmaceuticals in a research note on Monday, July 10th. TheStreet upgraded shares of Ionis Pharmaceuticals from a d+ rating to a c- rating in a research note on Wednesday, July 5th. Finally, Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a hold rating to a buy rating and set a $58.00 price objective on the stock in a research note on Wednesday, July 12th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $45.38.

Shares of Ionis Pharmaceuticals (NASDAQ IONS) traded up 0.51% during mid-day trading on Thursday, reaching $53.04. 523,932 shares of the company were exchanged. The company’s 50 day moving average price is $52.96 and its 200 day moving average price is $46.75. The firm’s market capitalization is $6.58 billion. Ionis Pharmaceuticals has a 12 month low of $24.58 and a 12 month high of $60.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Tuesday, May 9th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.13. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. The business had revenue of $110.30 million for the quarter, compared to the consensus estimate of $86.03 million. During the same period in the previous year, the firm earned ($0.52) EPS. The business’s revenue for the quarter was up 199.2% on a year-over-year basis. Equities analysts anticipate that Ionis Pharmaceuticals will post ($0.15) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/sanford-c-bernstein-initiates-coverage-on-ionis-pharmaceuticals-inc-ions/1464249.html.

In related news, Chairman Stanley T. Crooke sold 16,500 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $52.45, for a total transaction of $865,425.00. Following the transaction, the chairman now owns 53,014 shares of the company’s stock, valued at approximately $2,780,584.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP C Frank Bennett sold 10,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $59.29, for a total transaction of $592,900.00. Following the transaction, the senior vice president now directly owns 25,041 shares in the company, valued at approximately $1,484,680.89. The disclosure for this sale can be found here. Insiders have sold a total of 54,379 shares of company stock worth $2,946,052 in the last three months. 1.86% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the company. Hanseatic Management Services Inc. bought a new stake in shares of Ionis Pharmaceuticals during the first quarter valued at approximately $138,000. Westpac Banking Corp acquired a new stake in Ionis Pharmaceuticals during the first quarter worth about $171,000. Cheyne Capital Management UK LLP acquired a new stake in Ionis Pharmaceuticals during the second quarter worth about $249,000. Capstone Asset Management Co. increased its stake in Ionis Pharmaceuticals by 10.3% in the first quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock worth $207,000 after buying an additional 480 shares during the period. Finally, World Asset Management Inc increased its stake in Ionis Pharmaceuticals by 27.3% in the first quarter. World Asset Management Inc now owns 5,427 shares of the company’s stock worth $218,000 after buying an additional 1,163 shares during the period. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.